Negative hyper-selection of patients with HER2-positive and RAS wild-type metastatic colorectal cancer receiving dual HER2 blockade: the PRESSING-HER2 study
we hypothesized that genomic-based hyper-selection may refine the prognostic stratification of patients receiving dual HER2 blockade. To this aim, we conducted a multinational effort aimed at investigating the prognostic performance of a panel of rare genomic drivers of primary resistance (i.e. the PRESSING-HER2 panel) and HER2 CNV, both assessed by NGS, in patients with HER2-positive and RAS wild-type mCRC receiving dual HER2 blockade.